Novel Treatment Advances and Approaches
in the Prevention and Management of
Cytomegalovirus (CMV) Infection
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live webinar held on August 22, 2018. If you participated in
the live session, you are not eligible for continuing education
credits from this archive.
This activity is valid from September 15, 2018 to September 30, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by an
educational grant from
Merck & Co.
Cytomegalovirus (CMV) infection remains a frequent complication in
hematopoietic stem cell transplantation (HSCT) and solid organ
transplantation (SOT) recipients. In addition to causing a variety
of end-organ diseases, CMV infection is also associated with
rejection after SOT and with graft versus host disease (GVHD) after
HSCT. Antiviral prophylaxis is effective against direct and indirect
effects of CMV infection. Preemptive therapy, more commonly used
after HSCT, is based on surveillance, and targets therapy to
patients at highest risk. Novel antiviral therapies with different
mechanisms of action have recently become available giving
healthcare professionals new options in the management of this
infection. This program will take a look at those advances and
provide up to date strategies for the management of CMV infection.
Upon completion of this
activity, participants will be able to:
Discuss the impact and burden of CMV
infection in transplant recipients
Examine the efficacy and safety
profiles of novel antivirals for the prevention and management
of CMV in haematopoietic stem-cell transplant (HSCT) recipients
Identify patients who may benefit
from antiviral treatment for CMV infection
Optimize clinical and economic
strategies in the prevention of CMV in HSCT recipients
||Roy F. Chemaly, MD, MPH,
Professor of Medicine
Director, Infection Control Section
Director of Clinical Virology
University of Texas MD Anderson Cancer Center
serves as a consultant for Oxford Immunotec, Chimerix,
Merck and Astellas. He has received grant/research
support from: Chimerix, Merck, Novartis, Oxford
Immunotec, and Shire.
In addition, Dr. Chemaly serves on the speaker's bureau
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This presentation is supported by
an educational grant from
Merck & Co.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue